InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
0.683564
-0.0113 (-1.63%)
At close: Jul 24, 2026, 4:00 PM EDT
0.6800
-0.0036 (-0.52%)
After-hours: Jul 24, 2026, 6:34 PM EDT
InspireMD Revenue
InspireMD had revenue of $3.40M in the quarter ending March 31, 2026, with 122.24% growth. This brings the company's revenue in the last twelve months to $10.85M, up 54.38% year-over-year. In the year 2025, InspireMD had annual revenue of $8.98M with 28.11% growth.
Revenue (ttm)
$10.85M
Revenue Growth
+54.38%
P/S Ratio
2.95
Revenue / Employee
$85,417
Employees
127
Market Cap
32.02M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.98M | 1.97M | 28.11% |
| Dec 31, 2024 | 7.01M | 804.00K | 12.96% |
| Dec 31, 2023 | 6.21M | 1.03M | 20.00% |
| Dec 31, 2022 | 5.17M | 676.00K | 15.04% |
| Dec 31, 2021 | 4.50M | 2.01M | 80.89% |
| Dec 31, 2020 | 2.49M | -1.24M | -33.22% |
| Dec 31, 2019 | 3.72M | 120.00K | 3.33% |
| Dec 31, 2018 | 3.60M | 840.00K | 30.42% |
| Dec 31, 2017 | 2.76M | 867.00K | 45.78% |
| Dec 31, 2016 | 1.89M | -416.00K | -18.01% |
| Dec 31, 2015 | 2.31M | -508.00K | -18.03% |
| Dec 31, 2014 | 2.82M | -2.06M | -42.17% |
| Jun 30, 2013 | 4.87M | -476.00K | -8.90% |
| Jun 30, 2012 | 5.35M | -655.00K | -10.91% |
| Dec 31, 2011 | 6.00M | 1.06M | 21.32% |
| Dec 31, 2010 | 4.95M | 1.54M | 45.09% |
| Dec 31, 2009 | 3.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 428.57M |
| Nortech Systems | 121.79M |
| TELA Bio | 80.81M |
| Myomo | 41.21M |
| Cytosorbents | 37.20M |
| QT Imaging Holdings | 22.66M |
| Baird Medical Investment Holdings | 22.54M |
| Pulsenmore | 12.55M |
NSPR News
- 6 weeks ago - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - GlobeNewsWire
- 6 weeks ago - InspireMD enrolls first patient in CGUARDIANS III study - TheFly
- 6 weeks ago - InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures - GlobeNewsWire
- 2 months ago - InspireMD Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 2 months ago - InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - InspireMD price target lowered to $3 from $4 at Piper Sandler - TheFly
- 2 months ago - InspireMD reports Q1 EPS (16c), consensus (18c) - TheFly